Background: In humans, methane (CH4) is exclusively produced by the intestinal microbiota and has been implicated in several conditions including cardiovascular disease. After microbial production of CH4 in the gut, it steadily crosses into the systemic circulation and reaches the lungs where it can be detected in the exhaled breath, as a surrogate measure for intestinal CH4 production. Recent reports have shown an association between CH4 and vagal dysfunction as well as the inhibition of CH4 activity on ileal contractions with atropine, suggesting its action on the parasympathetic nervous system. Given these findings, we hypothesized that CH4 may be affecting resting heart rate (HR) based on the potential effect of CH4 on the vagus nerve. Objectives: Given its possible role in the parasympathetic nervous system, we aimed to study the relationship between breath CH4 and resting HR in humans. Additionally, we performed a longitudinal study analyzing the change in HR and its association with breath CH4 over time. Methods: First, we reviewed 1,126 subjects and compared HR in subjects with detectable and undetectable breath CH4. Second, we performed a post hoc analysis of a randomized control trial to compare the change in HR for those who had an increase in breath CH4 versus those that had a decrease in breath CH4 over 14 weeks. Last, we assessed whether a larger decrease in CH4 is associated with a larger increase in HR over time. Results: In the retrospective cohort, subjects with detectable CH4 had a lower HR compared to those with undetectable CH4 (73.0 ± 0.83 vs. 76.0 ± 0.44 beats/min, p = 0.01). In the post hoc analysis, a decrease in CH4 over time was associated with an increase in HR (median ∆ = 6.5 ± 8.32 beats/min, p = 0.0006). Last, we demonstrated a biological gradient whereby a larger drop in CH4 was associated with a greater increase in HR (R = −0.31, p = 0.03). Conclusion: Our findings suggest a potential role for the microbiome (and specifically CH4 from methanogens) to regulate HR. Considering these findings, mechanistic studies are warranted to further investigate this potential novel microbiome-neurocardiac axis.

1.
Adkins
C
,
Rezaie
A
.
Small intestinal bacterial overgrowth and coronary artery disease: what is in the CArDs?
Dig Dis Sci
.
2018 Feb
;
63
(
2
):
271
2
. .
2.
Bond
JH
,
Engel
RR
,
Levitt
MD
.
Factors influencing pulmonary methane excretion in man. An indirect method of studying the in situ metabolism of the methane-producing colonic bacteria
.
J Exp Med
.
1971 Mar
;
133
(
3
):
572
88
. .
3.
Nose
K
,
Nunome
Y
,
Kondo
T
,
Araki
S
,
Tsuda
T
.
Identification of gas emanated from human skin: methane, ethylene, and ethane
.
Anal Sci
.
2005 Jun
;
21
(
6
):
625
8
. .
4.
Kim
G
,
Deepinder
F
,
Morales
W
,
Hwang
L
,
Weitsman
S
,
Chang
C
,
Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath
.
Dig Dis Sci
.
2012 Dec
;
57
(
12
):
3213
8
.
5.
Song
Y
,
Liu
Y
,
Qi
B
,
Cui
X
,
Dong
X
,
Wang
Y
,
Association of small intestinal bacterial overgrowth with heart failure and its prediction for short-term outcomes
.
J Am Heart Assoc
.
2021 Apr 6
;
10
(
7
):
e015292
.
6.
Pimentel
M
,
Lin
HC
,
Enayati
P
,
van den Burg
B
,
Lee
HR
,
Chen
JH
,
Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity
.
Am J Physiol Gastrointest Liver Physiol
.
2006 Jun
;
290
(
6
):
G1089
95
.
7.
Suri
J
,
Kataria
R
,
Malik
Z
,
Parkman
HP
,
Schey
R
.
Elevated methane levels in small intestinal bacterial overgrowth suggests delayed small bowel and colonic transit
.
Medicine
.
2018 May
;
97
(
21
):
e10554
. .
8.
Pimentel
M
,
Saad
RJ
,
Long
MD
,
Rao
SSC
.
ACG clinical guideline: small intestinal bacterial overgrowth
.
Am J Gastroenterol
.
2020 Feb
;
115
(
2
):
165
78
.
9.
Park
YM
,
Lee
YJ
,
Hussain
Z
,
Lee
YH
,
Park
H
.
The effects and mechanism of action of methane on ileal motor function
.
Neurogastroenterol Motil
.
2017 Sep
;
29
(
9
). .
10.
Robinson-Papp
J
,
Nmashie
A
,
Pedowitz
E
,
Benn
EKT
,
George
MC
,
Sharma
S
,
Vagal dysfunction and small intestinal bacterial overgrowth: novel pathways to chronic inflammation in HIV
.
AIDS
.
2018 Jun 1
;
32
(
9
):
1147
56
.
11.
Schunemann
H
,
Hill
S
,
Guyatt
G
,
Akl
EA
,
Ahmed
F
.
The GRADE approach and Bradford Hill’s criteria for causation
.
J Epidemiol Community Health
.
2011 May
;
65
(
5
):
392
5
.
12.
Chaudhary
PP
,
Conway
PL
,
Schlundt
J
.
Methanogens in humans: potentially beneficial or harmful for health
.
Appl Microbiol Biotechnol
.
2018 Apr
;
102
(
7
):
3095
104
. .
13.
Takakura
W
,
Oh
SJ
,
Singer-Englar
T
,
Mirocha
J
,
Leite
G
,
Fridman
A
,
Comparing the rates of methane production in patients with and without appendectomy: results from a large-scale cohort
.
Sci Rep
.
2020 Jan 21
;
10
(
1
):
867
.
14.
Lin
L
,
Koblin
DD
,
Wang
HH
.
Effects of halothane on the nicotinic acetylcholine receptor from Torpedo californica
.
Biochem Pharmacol
.
1995 Apr 18
;
49
(
8
):
1085
9
. .
15.
Wang
W
,
Huang
X
,
Li
J
,
Sun
A
,
Yu
J
,
Xie
N
,
Methane suppresses microglial activation related to oxidative, inflammatory, and apoptotic injury during spinal cord injury in rats
.
Oxid Med Cell Longev
.
2017
;
2017
:
2190897
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.